Welireg - Beechwood Capital

Welireg belzutifan APPROVED

Drug Profile

ModalitySmall molecule

RoutePO

Therapy AreaOncology

Launch2021-08-13

US LOE2036-08-01

Peak Sales Est$2500M

Formulations[{"id":"welireg-po","doses":"120mg","route":"PO","setting":"PATIENT_SELF","frequency":"QD","is_prima

Companies

MRK (ORIGINATOR)100%

Mechanism: HIF-2α inhibitor

Expert: Hypoxia-inducible factor 2 alpha inhibitor

Everyday: Blocks protein that helps tumors grow in low oxygen

Targets: ["HIF-2A"]

Revenue History

Programs (2)

Indication	Stage	Key Study	Regional Status
VHL-RCC	APPROVED	Study 004	[{"stage":"APPROVED","region":"US","approval_date":"2021-08-13"}]
RCC (advanced)	PHASE3	LITESPARK-011	[]

Notes

First-in-class HIF-2α inhibitor. VHL disease, RCC indications. Label expansions ongoing.

Data from Supabase · Updated 2026-03-24